AuntMinnie

MARCH 26, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

Nuclear Medicine 306

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 306

Imaging Technology

JANUARY 30, 2025

30, 2025 Earlier this month, the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the Alzheimers Association released updated appropriate use criteria (AUC) for amyloid and tau PET imaging in patients with mild cognitive impairment, Alzheimers disease and other dementias. tim.hodson Thu, 01/30/2025 - 10:20 Jan.30,

Nuclear Medicine 52

Nuclear Medicine Imaging Patient Care Disease 52

AuntMinnie

JUNE 20, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

Nuclear Medicine 130

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 130

AuntMinnie

JANUARY 8, 2025

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the Alzheimers Association have released new appropriate use criteria for brain PET imaging of amyloid and tau pathology related to cognitive impairment and Alzheimers disease. Since then, the U.S. There are three PET radiotracers labeled with F-18 approved by the U.S.

Nuclear Medicine 290

Nuclear Medicine Imaging Radiopharmaceuticals Medicare 290

Imaging Technology

JANUARY 14, 2025

8, 2025 The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the Alzheimers Association have released updated appropriate use criteria (AUC) for amyloid and tau PET imaging in patients with mild cognitive impairment, Alzheimers disease and other dementias. tim.hodson Tue, 01/14/2025 - 16:48 Jan.8, Since then, the U.S.

Nuclear Medicine 52

Nuclear Medicine Imaging Patient Care PET Scan 52

Global Radiology CME

DECEMBER 21, 2024

A nuclear medicine hepatobiliary scan was also performed (not shown) and demonstrated no radiopharmaceutical present in the gallbladder due to cystic duct obstruction. Interventional approaches to gallbladder disease. A transperitoneal route is favored in patients with coagulopathy or diffuse liver disease [1]. 2022;16(1):49-54.

Education 52

Education Global Radiology Nuclear Medicine Ultrasound 52